Moderna (MRNA) Capital Expenditures Growth (3y) (2021 - 2026)
Powered by 
Analysis
Moderna (MRNA) Capital Expenditures Growth (3y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | 23.70% |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | 0.24% |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | 23.48% |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 63.07% |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | -45.93% |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | - |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 29.63% |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | -16.79% |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | - |
| 10 | Insmed | 26.19 Bn | 25.03 Bn | 358.27 Mn | 27.08% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -45.93% |
| Mar 31, 2026 | -18.13% |
| Dec 31, 2025 | -24.88% |
| Sep 30, 2025 | -28.16% |
| Jun 30, 2025 | -67.45% |
| Mar 31, 2025 | -3.94% |
| Dec 31, 2024 | 63.24% |
| Sep 30, 2024 | 15.11% |
| Jun 30, 2024 | 82.38% |
| Mar 31, 2024 | 77.58% |
| Dec 31, 2023 | 109.28% |
| Sep 30, 2023 | 94.59% |
| Jun 30, 2023 | 135.13% |
| Mar 31, 2023 | 152.73% |
| Dec 31, 2022 | 134.79% |
| Sep 30, 2022 | 136.70% |
| Jun 30, 2022 | 177.89% |
| Mar 31, 2022 | 110.62% |
| Dec 31, 2021 | 106.45% |
| Sep 30, 2021 | 55.88% |